| (Values in U.S. Thousands) | Jun, 2022 | Jun, 2021 | Jun, 2020 | Jun, 2019 | Jun, 2018 |
| Sales | 0 | 0 | 0 | 0 | 0 |
| Sales Growth | unch | unch | unch | unch | unch |
| Net Income | -113,430 | -26,720 | -11,420 | -18,020 | -9,150 |
| Net Income Growth | -324.51% | -133.98% | +36.63% | -96.94% | -282.85% |
Enochian Biosciences Inc
(ENOB)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
by (Cboe BZX)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
[[ item.lastPriceExt ]]
[[ item.priceChangeExt ]]
([[ item.percentChangeExt ]])
[[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Enochian BioSciences Inc. engages in the research and development, manufacturing and clinical trials of pharmaceutical and biological products for the human treatment of HIV and cancer. The company's product pipeline consists of ENO-1001, ENO-2001, ENO-3001, ENO-1002, ENO-5001 and ENO-4001. Enochian BioSciences Inc. is based in Los Angeles, United States.